指南与共识消化道肿瘤与早癌

AGA临床实践更新:结直肠肿瘤化学预防专家综述

AGA Clinical Practice Update on Chemoprevention for Colorectal Neoplasia: Expert Review.
指南 / 共识 · Clin Gastroenterol Hepatol · 2021-02-10

美国胃肠病学会专家综述提出结直肠肿瘤化学预防的最佳实践建议。低剂量阿司匹林可用于特定平均风险人群及CRC病史者,二甲双胍在2型糖尿病人群中可考虑,而非阿司匹林NSAIDs、钙剂、维生素D、叶酸和他汀不推荐用于化学预防。

要点

  • 低剂量阿司匹林用于<70岁、预期寿命≥10年、10年CVD风险≥10%且非高出血风险者。
  • 有CRC病史者可考虑阿司匹林预防复发;2型糖尿病者可考虑二甲双胍。
  • 不推荐非阿司匹林NSAIDs、钙/维生素D、叶酸或他汀用于化学预防。

核心结论

  • 低剂量阿司匹林可用于特定平均风险人群降低CRC发病和死亡,有CRC病史者可考虑阿司匹林预防复发。
  • 2型糖尿病患者可考虑二甲双胍预防结直肠肿瘤,CRC合并2型糖尿病者可考虑二甲双胍降低死亡率。
  • 不推荐非阿司匹林NSAIDs、钙剂、维生素D、叶酸或他汀用于结直肠肿瘤化学预防。

研究设计与样本

  • 美国胃肠病学会(AGA)组织的专家综述,基于文献回顾提出最佳实践建议。
  • 未进行正式系统评价,未评级证据质量或推荐强度。
  • 范围排除膳食因素及遗传性综合征或炎症性肠病高危个体。

关键数值与推荐

  • 建议1:平均风险者若<70岁、预期寿命≥10年、10年心血管疾病风险≥10%且非高出血风险,应使用低剂量阿司匹林降低CRC发病和死亡。
  • 建议2:有CRC病史者,临床医生应考虑使用阿司匹林预防结直肠肿瘤复发。
  • 建议3:平均风险者不应使用非阿司匹林NSAIDs预防结直肠肿瘤,因心血管和胃肠道不良事件风险显著。
  • 建议4和5:2型糖尿病患者可考虑二甲双胍预防结直肠肿瘤;CRC合并2型糖尿病者可考虑二甲双胍降低死亡率。
  • 建议6-9:不应使用钙剂或维生素D(单用或联用)、叶酸、他汀预防结直肠肿瘤;有CRC病史者不应使用他汀降低死亡率。

临床怎么用

  • 对符合年龄、预期寿命、心血管风险和出血风险条件的平均风险人群,可与患者讨论使用低剂量阿司匹林进行CRC化学预防。
  • 有CRC病史者可考虑阿司匹林预防复发;2型糖尿病患者可考虑二甲双胍。
  • 避免使用非阿司匹林NSAIDs、钙剂、维生素D、叶酸或他汀进行结直肠肿瘤化学预防。

局限性

  • 本综述未进行正式系统评价,未评级证据质量或推荐强度。
  • 范围排除膳食因素及遗传性综合征或炎症性肠病高危个体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DESCRIPTION: The purpose of this expert review is to describe the role of medications for the chemoprevention of colorectal neoplasia. Neoplasia is defined as precancerous lesions (e.g., adenoma and sessile serrated lesion) or cancer. The scope of this review excludes dietary factors and high-risk individuals with hereditary syndromes or inflammatory bowel disease. METHODS: The best practice advice statements are based on a review of the literature to provide practical advice. A formal systematic review and rating of the quality of evidence or strength of recommendation were not performed. BEST PRACTICE ADVICE 1: In individuals at average risk for CRC who are (1) younger than 70 years with a life expectancy of at least 10 years, (2) have a 10-year cardiovascular disease risk of at least 10%, and (3) not at high risk for bleeding, clinicians should use low-dose aspirin to reduce CRC incidence and mortality. BEST PRACTICE ADVICE 2: In individuals with a history of CRC, clinicians should consider using aspirin to prevent recurrent colorectal neoplasia. BEST PRACTICE ADVICE 3: In individuals at average risk for CRC, clinicians should not use non-aspirin NSAIDs to prevent colorectal neoplasia because of a substantial risk of cardiovascular and gastrointestinal adverse events. BEST PRACTICE ADVICE 4: In individuals with type 2 diabetes, clinicians may consider using metformin to prevent colorectal neoplasia. BEST PRACTICE ADVICE 5: In individuals with CRC and type 2 diabetes, clinicians may consider using metformin to reduce mortality. BEST PRACTICE ADVICE 6: Clinicians should not use calcium or vitamin D (alone or together) to prevent colorectal neoplasia. BEST PRACTICE ADVICE 7: Clinicians should not use folic acid to prevent colorectal neoplasia. BEST PRACTICE ADVICE 8: In individuals at average risk for CRC, clinicians should not use statins to prevent colorectal neoplasia. BEST PRACTICE ADVICE 9: In individuals with a history of CRC, clinicians should not use statins to reduce mortality.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Liang PS, Shaukat A, Crockett SD, et al. AGA Clinical Practice Update on Chemoprevention for Colorectal Neoplasia: Expert Review. Clin Gastroenterol Hepatol. 2021. PMID: 33581359. doi:10.1016/j.cgh.2021.02.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。